Rearrangement of the Bcl-6 Gene as a Prognostic Marker in Diffuse Large-Cell Lymphoma

Rearrangement of the Bcl-6 Gene as a Prognostic Marker in Diffuse Large-Cell Lymphoma

Current therapy can induce a long-term remission in half the patients with diffuse lymphomas with a large-cell component (DLLC), but more intensive treatment has the potential to improve outcome. Rearrangement of a novel candidate proto-oncogene, bcl-6, correlates with a favorable clinical outcome i...

Full description

Saved in:
Bibliographic Details
Main Authors: Offit, K., Louie, D.C., Parsa, N. Z., Leung, Denis H. Y., Portlock, C., Ye, B.H., Lista, F., Filippa, D.A., Rosenbaum, A., Ladanyi, M., Jhanwar, S., Dalla-Favera, R., Changanti, R.S.K.
Format: text
Language:English
Published: Institutional Knowledge at Singapore Management University 1994
Subjects:
Econometrics
Medicine and Health Sciences
Online Access:https://ink.library.smu.edu.sg/soe_research/92
https://ink.library.smu.edu.sg/context/soe_research/article/1091/viewcontent/nejm199407143310202_pv.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Singapore Management University
Language: English
Description
Summary:Current therapy can induce a long-term remission in half the patients with diffuse lymphomas with a large-cell component (DLLC), but more intensive treatment has the potential to improve outcome. Rearrangement of a novel candidate proto-oncogene, bcl-6, correlates with a favorable clinical outcome in DLLC and may thus serve as a prognostic marker.

Similar Items